Inter-laboratory comparison of a serum fibroblast growth factor receptor 3 (FGFR3) antibody test in sensory neuropathies
We provide and evaluate a detailed ELISA protocol for anti-FGFR3 diagnostic assessment. Positive results near the threshold should be interpreted cautiously. Anti-FGFR3 DRG staining may be a useful confirmatory method and could increase diagnostic specificity. This study facilitates future studies on the diagnostic relevance of anti-FGFR3 autoantibodies in sensory neuropathies.
Authors
- Jean‐Philippe Camdessanché (ORCID: https://orcid.org/0000-0002-5282-6707)
- Claudia Sommer (ORCID: https://orcid.org/0000-0002-7064-5002)
- Sabine Seefried (ORCID: https://orcid.org/0009-0004-0046-3459)
- Luise Appeltshauser (ORCID: https://orcid.org/0000-0001-5248-4009)
- Luisa Kreß
- Kathrin Doppler (ORCID: https://orcid.org/0000-0003-2883-0009)
- Nurcan Üçeyler (ORCID: https://orcid.org/0000-0001-6973-6428)
- Yannick Tholance (ORCID: https://orcid.org/0000-0002-1826-3031)
- Jean‐Christophe Antoine (ORCID: https://orcid.org/0000-0003-4944-9362)
- Christian P. Moritz (ORCID: https://orcid.org/0000-0002-9294-2323)
- Anastasia Barcic
- François Lassablière
- Lena Reinhardt
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Institut NeuroMyoGène (FR)
- Universitätsklinikum Würzburg (DE)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1604456
- Citations
- 1
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81